novel opv2
Vaccineexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
2
Earliest trial started Oct 22, 2018 (NCT04544787)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- PoliovirusImmunity, active
Poliovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07010822 | Phase 3 | Dec 8, 2025 | Bill and Melinda Gates Foundation, Fidec Corporation, International Center for Diarrheal Disease Research |
| NCT06114810 | Phase 4 | Nov 30, 2023 | Centers for Disease Control and Prevention (CDC), Government of Bangladesh, International Center for Diarrheal Disease Research |
| NCT05677256 | Phase 4 | Oct 12, 2023 | Bill and Melinda Gates Foundation, Fidec Corporation |
| NCT05033561 | Phase 3 | Dec 31, 2021 | Bill and Melinda Gates Foundation, Fidec Corporation |
| NCT04544787 | Phase 2 | Oct 22, 2018 | Bill and Melinda Gates Foundation, Celerion, Centers for Disease Control and Prevention (CDC), PATH, University of Antwerp |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 4 | 0 | 3 | 2018 |
| Fidec Corporation | Academic/Hospital | 3 | 3 | 2 | 2021 |
| Centers for Disease Control and Prevention (CDC) | Government | 2 | 0 | 2 | 2018 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 2 | 1 | 2 | 2023 |
| Celerion | For profit | 1 | 0 | 1 | 2018 |
| Government of Bangladesh | Academic/Hospital | 1 | 0 | 1 | 2023 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Antwerp | Academic/Hospital | 1 | 1 | 1 | 2018 |
8 organizations
Page 1 / 1